{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:22:10Z","timestamp":1792264930594,"version":"4.4.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s40265-023-01977-3","type":"journal-article","created":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T03:02:19Z","timestamp":1702522939000},"page":"99-104","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Zilucoplan: First Approval"],"prefix":"10.1007","volume":"84","author":[{"given":"Matt","family":"Shirley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,14]]},"reference":[{"key":"1977_CR1","unstructured":"US FDA. ZILBRYSQ (zilucoplan) injection, for subcutaneous use: US prescribing information. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216834s000lbl.pdf. Accessed 10 Nov 2023."},{"key":"1977_CR2","unstructured":"Pharmaceuticals and Medical Devices Agency. ZILBRYSQ\u00ae syringe for SC injections: Japanese prescribing information. 2023. https:\/\/www.pmda.go.jp\/english\/review-services\/reviews\/approved-information\/drugs\/0003.html. Accessed 10 Nov 2023."},{"issue":"5","key":"1977_CR3","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","volume":"22","author":"JF Howard Jr","year":"2023","unstructured":"Howard JF Jr, Bresch S, Genge A, et al. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol. 2023;22(5):395\u2013406.","journal-title":"Lancet Neurol"},{"key":"1977_CR4","unstructured":"UCB. UCB announces approval of RYSTIGGO[\u00ae] (rozanolixizumab) and ZILBRYSQ[\u00ae] (zilucoplan) for the treatment of adult patients with generalized myasthenia gravis in Japan [media release]. 2023. https:\/\/www.ucb.com\/stories-media\/Press-Releases\/article\/UCB-announces-approval-of-RYSTIGGOR-rozanolixizumab-and-ZILBRYSQR-zilucoplan-for-the-treatment-of-adult-patients-with-generalized-myasthenia-gravis-in-Japan. Accessed 25 Sep 2023."},{"key":"1977_CR5","unstructured":"US FDA. Zilbrysq NDA approval. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2023\/216834Orig1s000ltr.pdf. Accessed 10 Nov 2023."},{"key":"1977_CR6","unstructured":"UCB. UCB announces European Commission approval of ZILBRYSQ\u00ae (zilucoplan) for the treatment of adults with generalized Myasthenia Gravis [media release]. https:\/\/www.ucb.com\/sites\/default\/files\/press_files\/ac12afd8f326ccb1.pdf. Accessed 5 Dec 2023."},{"key":"1977_CR7","doi-asserted-by":"crossref","unstructured":"Kulasekararaj AG, Lehtinen A-E, Forsyth C, et al. Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria. Haematologica. 2023.","DOI":"10.3324\/haematol.2022.281780"},{"issue":"2","key":"1977_CR8","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1016\/S2665-9913(23)00003-6","volume":"5","author":"AL Mammen","year":"2023","unstructured":"Mammen AL, Amato AA, Dimachkie MM, et al. Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial. Lancet Rheumatol. 2023;5(2):e67-76.","journal-title":"Lancet Rheumatol."},{"issue":"17 Suppl 2","key":"1977_CR9","first-page":"PL5.004","volume":"100","author":"S Paganoni","year":"2023","unstructured":"Paganoni S, Berry J, Quintana M, et al. Results from the first four regimens of the HEALEY ALS Platform Trial [abstract]. Neurology. 2023;100(17 Suppl 2):PL5.004.","journal-title":"Neurology"},{"issue":"1","key":"1977_CR10","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12931-022-02126-2","volume":"23","author":"E De Leeuw","year":"2022","unstructured":"De Leeuw E, Van Damme KFA, Declercq J, et al. Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial. Respir Res. 2022;23(1):202.","journal-title":"Respir Res"},{"issue":"1","key":"1977_CR11","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1186\/s13063-020-04584-9","volume":"21","author":"T Wilkinson","year":"2020","unstructured":"Wilkinson T, Dixon R, Page C, et al. ACCORD: a multicentre, seamless, phase 2 adaptive randomisation platform study to assess the efficacy and safety of multiple candidate agents for the treatment of COVID-19 in hospitalised patients: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):691.","journal-title":"Trials"},{"issue":"1","key":"1977_CR12","first-page":"A1648","volume":"207","author":"A Ako","year":"2023","unstructured":"Ako A, Glatt S, Lalla M, et al. Efficacy and safety of zilucoplan for the treatment of COVID-19 in hospitalized patients: part of the COMMUNITY platform trial. Am J Respir Crit Care Med. 2023;207(1):A1648.","journal-title":"Am J Respir Crit Care Med"},{"key":"1977_CR13","unstructured":"UCB. UCB completes the acquisition of Ra Pharmaceuticals - to deliver differentiated therapies to patients [media release]. https:\/\/www.ucb.com\/stories-media\/Press-Releases\/article\/UCB-completes-the-acquisition-of-Ra-Pharmaceuticals-to-deliver-differentiated-therapies-to-patients. Accessed 2 Apr 2020."},{"key":"1977_CR14","unstructured":"Ra Pharmaceuticals. Ra Pharmaceuticals reports third quarter 2018 financial results and provides corporate update [media release]. 2018. http:\/\/www.rapharma.com. Accessed 19 Nov 2018."},{"key":"1977_CR15","doi-asserted-by":"publisher","first-page":"1213920","DOI":"10.3389\/fimmu.2023.1213920","volume":"14","author":"GQ Tang","year":"2023","unstructured":"Tang GQ, Tang Y, Dhamnaskar K, et al. Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation. Front Immunol. 2023;14:1213920.","journal-title":"Front Immunol"},{"issue":"5","key":"1977_CR16","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1001\/jamaneurol.2019.5125","volume":"77","author":"JF Howard Jr","year":"2020","unstructured":"Howard JF Jr, Nowak RJ, Wolfe GI, et al. Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial. JAMA Neurol. 2020;77(5):582\u201392.","journal-title":"JAMA Neurol"},{"issue":"5","key":"1977_CR17","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/mus.22140","volume":"44","author":"S Muppidi","year":"2011","unstructured":"Muppidi S, Wolfe GI, Conaway M, et al. MG-ADL: still a relevant outcome measure. Muscle Nerve. 2011;44(5):727\u201331.","journal-title":"Muscle Nerve"},{"issue":"S1","key":"1977_CR18","first-page":"S131","volume":"66","author":"A Genge","year":"2022","unstructured":"Genge A, Hussain Y, Kaminski HJ, et al. Safety and tolerability of zilucoplan in RAISE-XT: a multicenter, open-label extension study in patients with myasthenia gravis [abstract plus poster]. Muscle Nerve. 2022;66(S1):S131.","journal-title":"Muscle Nerve"},{"key":"1977_CR19","unstructured":"Leite MI, Bresch S, Freimer M, et al. Long-term safety, efficacy and self-injection satisfaction with zilucoplan in myasthenia gravis: an interim analysis of RAISE-XT [abstract and poster EPO-219]. In: EAN 2023. 2023."}],"updated-by":[{"DOI":"10.1007\/s40265-024-02019-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01977-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-023-01977-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01977-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T02:10:47Z","timestamp":1710814247000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-023-01977-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,14]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["1977"],"URL":"https:\/\/doi.org\/10.1007\/s40265-023-01977-3","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40265-024-02019-2","asserted-by":"object"}]},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,14]]},"assertion":[{"value":"14 December 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2024","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40265-024-02019-2","URL":"https:\/\/doi.org\/10.1007\/s40265-024-02019-2","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Matt Shirley is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}